The FDA should limit its approval of the new Alzheimer’s drug
Washington Post,
Jerry Avorn is a professor of medicine at Harvard Medical School and co-director of the Program on Regulation, Therapeutics and…
Jerry Avorn is a professor of medicine at Harvard Medical School and co-director of the Program on Regulation, Therapeutics and…
Opinion > Second Opinions Waiting for the results of the SRP-9001 confirmatory trial may be a better move by May 18, 2023…
The diagnosis was news no parent ever wants to receive. Susan and Chris Finazzo heard it twice in two months.
For decades, scientists have been crying out for action. Will they finally be heard? The byzantine world of pharmaceutical…
For decades, scientists have been crying out for action. Will they finally be heard? The byzantine world of pharmaceutical…
The byzantine world of pharmaceutical regulation has recently broken into the public consciousness, causing a bit of a panic.
The controversial approval of the Alzheimer's disease medicine aducanumab has drawn new attention to the Biden administration's…
Cela faisait 18 ans qu’un médicament pour combattre cette maladie neurodégénérative n’avait pas reçu d’autorisation de mise sur…
Science The first drug approved for the disease in 18 years, Aduhelm shows only scant benefit in clinical trials, and experts…
The Biden administration is in the process of reviewing potential candidates for the next Commissioner of the US Food and Drug…
Balancing safety while also supporting innovation to help patients access new therapies means that the pendulum at the Food and…
The Food and Drug Administration’s rejection Monday of Sarepta Therapeutics’ second drug for Duchenne muscular dystrophy came…
Editor’s note: The opinions in this article are the author’s, as published by our content partner, and do not necessarily…
The federal budget tabled by Finance Minister Bill Morneau contains two significant announcements dealing with prescription…
The September approval of a therapy for Duchenne muscular dystrophy (DMD) continues to rankle many who say the evidence did not…
MedpageToday by Kristina Fiore Associate Editor, MedPage Today November 01, 2016 Here's how a pharmacy benefit manager kept the…
Finally, there’s a drug available to treat Duchenne muscular dystrophy (DMD), a rare, fatal genetic muscle-wasting disease that…
October 28th, 2016 Xconomy National — The 2016 election is (thankfully) almost here, and as one biotech analyst noted this week…
Not all decisions of the FDA are black and white. On one hand, the agency is charged with the responsibility of protecting the…
External FDA expert Aaron Kesselheim, who advised against the regulator approving Sarepta’s ($SRPT) new and highly…
External FDA expert Aaron Kesselheim, who advised against the regulator approving Sarepta’s ($SRPT) new and highly…
External FDA expert Aaron Kesselheim, who advised against the regulator approving Sarepta’s ($SRPT) new and highly…
Two of Harvard’s top FDA policy experts, Aaron Kesselheim and Jerry Avorn, have expressed some deep concerns about the agency’s…